Press release
Hereditary Angioedema Pipeline Drugs Report 2025 by DelveInsight | In-depth clinical trials, emerging therapies, and evolving treatment landscape shaping the future of management
Discover the latest drugs and treatment options in the Hereditary Angioedema Pipeline. Dive into DelveInsight's comprehensive report today! @ Hereditary Angioedema Pipeline Outlook [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hereditary Angioedema Pipeline Report
* On 19 September 2025, BioCryst Pharmaceuticals conducted a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies. APeX-A, 7353-312, is a single-arm, open-label, multicenter study. The study will be conducted in countries where berotralstat is not available either commercially or via another mechanism and is planned in countries where pediatric participants have been enrolled in BCX7353-304 (Study 304).
* On 17 September 2025, KalVista Pharmaceuticals Ltd . announced a study of KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
* DelveInsight's Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
* The leading Hereditary Angioedema Companies such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
* Promising Hereditary Angioedema Pipeline Therapies such as NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
Stay ahead with the most recent pipeline outlook for Hereditary Angioedema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hereditary Angioedema Treatment Drugs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hereditary Angioedema Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hereditary Angioedema Pipeline Report also highlights the unmet needs with respect to Hereditary Angioedema.
Hereditary Angioedema Overview
Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting.
Hereditary Angioedema Emerging Drugs Profile
* KVD900: KalVista Pharmaceuticals
KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020. Currently, the drug is inthe Phase III stage of development for the treatment of Hereditary angioedema.
* PHA121: Pharvaris
PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.
* BMN 331: BioMarin Pharmaceutical
BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.
Explore groundbreaking therapies and clinical trials in the Hereditary Angioedema Pipeline. Access DelveInsight's detailed report now! @ New Hereditary Angioedema Drugs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hereditary Angioedema Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Angioedema with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
* Hereditary Angioedema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hereditary Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Angioedema market
Hereditary Angioedema Companies
Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
Hereditary Angioedema Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
Unveil the future of Hereditary Angioedema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hereditary Angioedema Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hereditary Angioedema Pipeline Report
* Coverage- Global
* Hereditary Angioedema Companies- Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
* Hereditary Angioedema Pipeline Therapies- NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
* Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hereditary Angioedema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hereditary Angioedema Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hereditary angioedema: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hereditary angioedema - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Hereditary angioedema Collaboration Deals
* Late Stage Products (Phase III and NDA)
* KVD900: KalVista Pharmaceuticals
* Mid Stage Products (Phase II)
* PHA121: Pharvaris
* Early Stage Products (Phase I)
* BMN 331: BioMarin Pharmaceutical
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Hereditary angioedema Key Companies
* Hereditary angioedema Key Products
* Hereditary angioedema- Unmet Needs
* Hereditary angioedema- Market Drivers and Barriers
* Hereditary angioedema- Future Perspectives and Conclusion
* Hereditary angioedema Analyst Views
* Hereditary angioedema Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-angioedema-pipeline-drugs-report-2025-by-delveinsight-indepth-clinical-trials-emerging-therapies-and-evolving-treatment-landscape-shaping-the-future-of-management]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema Pipeline Drugs Report 2025 by DelveInsight | In-depth clinical trials, emerging therapies, and evolving treatment landscape shaping the future of management here
News-ID: 4190587 • Views: …
More Releases from ABNewswire
Why Are Miami Residents Turning To Used Cars Nowadays?
Miami, FL - The demand for used cars in miami [https://www.autoworldofamerica.com/] is continuously rising in the fast-changing automotive market. More drivers have discovered the advantages of purchasing pre-owned vehicles. Used cars are the go-to option for car buyers without compromising quality. They can save from the costs without affecting the used car performance, still reliability and offer variety.
Why choose Miami used cars?
The primary reason people are turning to used cars…
Rising Demand for Used Cars in Rialto: What's Driving the Market Trend?
Rialto, CA - The automotive market continues to evolve, and recent trends highlight the rise in demand for used cars in rialto [https://www.carfam.com/]. More residents seek affordable, reliable, and practical transportation options. The pre-owned vehicle sector has a major option for buyers across the city.
Over the past few years, the automotive industry has faced various changes due to:
economic shifts
supply chain disruptions
consumer preferences
These factors, combined with the ever-increasing cost of new…
Chronic Hepatitis B Virus Pipeline Drugs Report 2025 by DelveInsight | Latest re …
DelveInsight's "Chronic Hepatitis B Virus Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Hepatocellular Carcinoma Pipeline Drugs Report 2025: Exploring Novel Mechanisms …
DelveInsight's "Hepatocellular Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
